Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Classifier in Incidentally Discovered Low to Moderate Risk Lung Nodules

NCT04171492 is registered in ClinicalTrials.gov with Biodesix, Inc. as lead sponsor.

NCT NCT04171492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04171492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Classifier in Incidentally Discovered Low to Moderate Risk Lung Nodules
Lead sponsor
Biodesix, Inc.
Phase
Observational
Overall status
Active, not recruiting
Start date
December 18, 2020
Completion date
December 31, 2026
Enrollment
2,000 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

nodule solitary pulmonary, non-small cell carcinoma